This database contains 1058 studies, archived under the term: "aged"
Click here to filter this large number of results.
Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double-blind placebo controlled trial
Fox, Chris,
Crugel, Monica,
Maidment, Ian,
Auestad, Bjorn Henrik,
Coulton, Simon,
Treloar, Adrian,
Ballard, Clive,
Boustani, Malaz,
Katona, Cornelius,
Livingston, Gill
Background: Agitation in Alzheimer’s disease (AD) is common and associated with poor patient life-quality and carer distress. The best evidence-based pharmacological treatments are antipsychotics which have limited benefits with increased morbidity and mortality. There are no memantine trials in clinically significant agitation but post-hoc analyses in other populations found reduced agitation. We tested the primary […]
Faith-based cognitive behavioral therapy: easing depression in the elderly with cognitive decline
Minimizing depression in residential aged care facilities is a formidable challenge but doing so may improve quality of life and protect against dementia. A pilot project with residents with cognitive decline and concurrent depression tested the suitability of a faith-based cognitive behavioral therapy (CBT) intervention in reducing participant levels of depression, offering promising results.;
Cognitive stimulation therapy (CST) for people with dementia–who benefits most?
Aguirre, E.,
Hoare, Z.,
Streater, A.,
Spector, A.,
Woods, B.,
Hoe, J.,
Orrell, M.
Background: The efficacy of cognitive stimulation therapy (CST) has been demonstrated, but little is known about the characteristics of people with dementia, which may predict a more positive response to CST. This study sought to investigate which factors may predict response to CST.; Methods: Two hundred and seventy-two participants with dementia took part in a […]
Memantine and brain atrophy in Alzheimer’s disease: a 1-year randomized controlled trial
Wilkinson, David,
Fox, Nick C.,
Barkhof, Frederik,
Phul, Ravinder,
Lemming, Ole,
Scheltens, Philip
The primary objective of this study was to evaluate the rate of total brain atrophy (TBA) with serial magnetic resonance imaging (MRI), using the Brain Boundary Shift Integral (BBSI), in patients with probable Alzheimer’s disease (AD) over the course of 52 weeks of treatment with memantine or placebo. This was a multi-national, randomized, double-blind, placebo-controlled, […]
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study
Winblad, Bengt,
Andreasen, Niels,
Minthon, Lennart,
Floesser, Annette,
Imbert, Georges,
Dumortier, Thomas,
Maguire, R. Paul,
Blennow, Kaj,
Lundmark, Joens,
Staufenbiel, Matthias,
Orgogozo, Jean-Marc,
Graf, Ana
Background: Immunotherapy targeting the amyloid β (Aβ) peptide is a potential strategy to slow the progression of Alzheimer’s disease. We aimed to assess the safety and tolerability of CAD106, a novel active Aβ immunotherapy for patients with Alzheimer’s disease, designed to induce N-terminal Aβ-specific antibodies without an Aβ-specific T-cell response.; Methods: We did a phase […]
The Mental Activity and eXercise (MAX) trial: a randomized controlled trial to enhance cognitive function in older adults
Barnes, Deborah E.,
Santos-Modesitt, Wendy,
Poelke, Gina,
Kramer, Arthur F.,
Castro, Cynthia,
Middleton, Laura E.,
Yaffe, Kristine
Importance: The prevalence of cognitive impairment and dementia are projected to rise dramatically during the next 40 years, and strategies for maintaining cognitive function with age are critically needed. Physical or mental activity alone result in relatively small, domain-specific improvements in cognitive function in older adults; combined interventions may have more global effects.; Objective: To […]
Study of the use of antidepressants for depression in dementia: the HTA-SADD trial–a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine
Banerjee, S.,
Hellier, J.,
Romeo, R.,
Dewey, M.,
Knapp, M.,
Ballard, C.,
Baldwin, R.,
Bentham, P.,
Fox, C.,
Holmes, C.,
Katona, C.,
Lawton, C.,
Lindesay, J.,
Livingston, G.,
McCrae, N.,
Moniz-Cook, E.,
Murray, J.,
Nurock, S.,
Orrell, M.,
O'Brien, J.,
Poppe, M.,
Thomas, A.,
Walwyn, R.,
Wilson, K.,
Burns, A.
Objective: Depression is common in dementia, causing considerable distress and other negative impacts. Treating it is a clinical priority, but the evidence base is sparse and equivocal. This trial aimed to determine clinical effectiveness of sertraline and mirtazapine in reducing depression 13 weeks post randomisation compared with placebo.; Design: Multicentre, parallel-group, double-blind placebo-controlled randomised controlled […]
Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures
Galasko, Douglas R,
Peskind, Elaine,
Clark, Christopher M.,
Quinn, Joseph F.,
Ringman, John M.,
Jicha, Gregory A.,
Cotman, Carl,
Cottrell, Barbara,
Montine, Thomas J.,
Thomas, Ronald G.,
Aisen, Paul
Objective: To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers.; Design: Double-blind, placebo-controlled clinical trial.; Setting: Academic medical centers.; Participants: Subjects with mild to moderate Alzheimer disease.; Intervention: Random assignment to treatment for 16 weeks with 800 IU/d of vitamin E (α-tocopherol) plus 500 mg/d of vitamin C […]